<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40761056</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1011-601X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Pakistan journal of pharmaceutical sciences</Title><ISOAbbreviation>Pak J Pharm Sci</ISOAbbreviation></Journal><ArticleTitle>The use of ticagrelor with clopidogrel in patients after interventional therapy for acutely coronary syndrome and effect on serum specificity indices.</ArticleTitle><Pagination><StartPage>1203</StartPage><EndPage>1212</EndPage><MedlinePgn>1203-1212</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.36721/PJPS.2025.38.4.REG.14377.1</ELocationID><Abstract><AbstractText>Acute coronary syndrome (ACS) is a severe form of coronary artery disease that poses a major challenge to clinical management. This study evaluated the effects of ticagrelor and clopidogrel on serum biomarkers and clinical outcomes after intervention in patients with ACS. 112 ACS patients (June 2023 to June 2024) were enrolled and randomized into two groups: control group (n=56) and study group (n=56). Both groups received clopidogrel treatment, while the study group was additionally treated with ticagrelor. Platelet aggregation rate, serum inflammatory markers, cardiac function indices (LVEF, LVEDD, LVESD), immune function, microcirculatory function (CFR, IMR), clinical efficacy, and adverse events were assessed at various time points. Postoperative indicators improved in both groups (P&lt;0.05). Platelet aggregation rate, inflammatory index level, LVEDD and LVESD, percentage of CD8+ T cellls, IMR level and incidence of adverse reactions were lower in Study group patients than in Control group (P&lt;0.05). Study group patients had higher LVEF, percentage of CD3+ T cellls, CD4+ T cellls, CFR level and clinical efficacy than Control group (P&lt;0.05). The efficacy of ticagrelor and clopidogrel in the post-interventional period in patients with ACS is definite and of high clinical value.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yangzhi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Practice, Lishui People's Hospital, Lishui City, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Limei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of General Practice, Lishui People's Hospital, Lishui City, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of General Practice, Lishui People's Hospital, Lishui City, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Pakistan</Country><MedlineTA>Pak J Pharm Sci</MedlineTA><NlmUniqueID>9426356</NlmUniqueID><ISSNLinking>1011-601X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>GLH0314RVC</RegistryNumber><NameOfSubstance UI="D000077486">Ticagrelor</NameOfSubstance></Chemical><Chemical><RegistryNumber>A74586SNO7</RegistryNumber><NameOfSubstance UI="D000077144">Clopidogrel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077486" MajorTopicYN="Y">Ticagrelor</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077144" MajorTopicYN="Y">Clopidogrel</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054058" MajorTopicYN="Y">Acute Coronary Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="Y">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010974" MajorTopicYN="N">Platelet Aggregation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>5</Day><Hour>3</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40761056</ArticleId><ArticleId IdType="doi">10.36721/PJPS.2025.38.4.REG.14377.1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>